Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Nature Chemical Biology|June 25, 2021
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growthBianca J Lee, Jacob A Boyer, G Leslie Burnett, et al.Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.Journal of Medicinal Chemistry|December 19, 2022
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated TumorsG Leslie Burnett, Yu C Yang, James B Aggen, et al.Science (New York, N.Y.)|August 17, 2023
Chemical remodeling of a cellular chaperone to target the active state of mutant KRASChristopher J Schulze, Kyle J Seamon, Yulei Zhao, et al.Science (New York, N.Y.)|July 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumorsCaroline Weller, G Leslie Burnett, Lingyan Jiang, et al.Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.Cancer Discovery|February 11, 2026
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint BlockadeXing Wei, Cristina Blaj, M Ali Al-Radhawi, et al.Pageof 4